Under the new collaboration agreement WuXi PharmaTech will synthesize compounds, according to AstraZeneca’s designs, which will further expand AstraZeneca’s global compound collection.
In April 2006, WuXi PharmaTech and AstraZeneca entered into a two-year $14 million collaboration agreement that WuXi PharmaTech successfully delivered more than 100,000 compounds two months ahead of schedule.
Ge Li, chairman and CEO of WuXi PharmaTech, said: “This new collaboration agreement further strengthens our already productive relationship with AstraZeneca, and it is the direct result of our research capability and firm commitment to quality and customer satisfaction.”